Navigation Links
Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
Date:11/30/2007

SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program in London on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT local time in the UK. Berthold Lensker, Ph.D., Executive Director of European Operations, will be providing a corporate overview of Amylin Pharmaceuticals.

The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

More information about the Nasdaq 20th Investor Program is available at: http://december.nasdaqconference.com/info.asp.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amy
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... TEL AVIV, Israel, BADAJOZ, Spain and SINGAPORE, August 5 ... been appointed as the,new Chief Executive Officer effective July ... 20 years of experience in sales,marketing and senior management ... VP of Marketing and Sales at UltraShape Ltd., a ...
... Lai-Goldman, Chief Medical Officer of LabCorp and Jack Ballantyne, ... ... Team, CARLSBAD, Calif., Aug. 5 GenVault Corporation ... Lai-Goldman and,Dr. Jack Ballantyne, have joined its Scientific Advisory ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,will hold ... Chairman and CEO, at,12:00pm EDT today, August 5, ... to discuss the preliminary results obtained from its,open-label, ...
Cached Biology Technology:Pollogen Announces Appointment of Ms. Yfat Scialom as Chief Executive Officer 2GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER 2
(Date:7/10/2014)... Foundation, a nonprofit organization funding cutting-edge, innovative research ... glaucoma and macular degeneration, today announced the recipients ... scientists in 19 U.S. states, the District of ... . , With these latest grants, BrightFocus ... research funding in 2014. , The research projects ...
(Date:7/10/2014)... ANN ARBOR Because the strong currents in the ... rupture of the oil pipeline beneath the channel would ... and Huron, according to a new University of Michigan ... one scenario examined in the study and accompanying animations, ... and Round Island after 12 hours and Bois Blanc ...
(Date:7/10/2014)... University Medical Center (CUMC) researchers have created a way ... pigmentosa (RP), a leading cause of vision loss. The ... induced pluripotent stem (iPS) cell technology to transform skin ... a patient-specific model for disease study and preclinical testing. ... Tsang, MD, PhD, showed that a form of RP ...
Breaking Biology News(10 mins):BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... Functioning much like gears in a machine, cellular motor ... including muscle contraction, cell migration and cellular growth processes. ... of The Scripps Research Institute report that motor proteins ... long-term memories. The findings add an unexpected dimension to ...
... twin awards from the National Science Foundation (NSF) totaling ... Computational Sciences (NICS) will add 300 teraflops to the ... have access to more than 200 million additional service ... available from NICS to over 800 million and benefitting ...
... from the U.S., the researchers surrounding Prof. Dr. Martina Havenith ... a so-termed Rapid Communication in the prestigious American chemistry journal, ... The journal,s independent reviewers evaluated the work as one of ... household antifreeze Temperatures of minus 1.8 C ...
Cached Biology News:UCI-Scripps study links cellular motors to memory 2NICS to add more than 300 Teraflops to the NSF’s computing capacity 2Why fish don't freeze in the Arctic Ocean 2
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: